{
    "clinical_study": {
        "@rank": "138038", 
        "arm_group": {
            "arm_group_label": "Arm A", 
            "arm_group_type": "Experimental", 
            "description": "All patients in the arm receive cetuximab combined with preoperative radiotherapy at first. 4-6 weeks after the rdiaotherapy\uff0cpatients receive right thoracotomy with three incisions radical surgery."
        }, 
        "brief_summary": {
            "textblock": "This study aim to investigate Changes in tumor tissue and serum biomarkers before and after\n      cetuximab combined with preoperative radiotherapy in locally advanced thoracic middle-lower\n      segment esophageal squamous cell carcinoma.We want to find one or more effective biomarkers\n      to predict and evaluate the patients who will be benefit from cetuximab combined with\n      preoperative radiotherapy."
        }, 
        "brief_title": "Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Middle or Lower Thoracic Esophageal Squamous Cell Carcinoma", 
        "condition": "Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        (1)18 to 65 years old,male or female (2)Pathologically or cytologically proven thoracic\n        middle-lower esophageal squamous cell carcinoma; (3)clinical stage II or stage III;\n        (4)Primary tumors can be measured; (5)Karnofsky score >70; (6)Estimated life expectancy of\n        at least 12 weeks; (7)reproductive age women should ensure that before entering the study\n        period contraception; (8)Hemoglobin\u226590.0g/dL,white blood cell count\uff08WBC\uff09\u2265 4000\n        cells/mm\u00b3,Platelet count\u2265100,000 cells/mm\u00b3; (9)Aspartate aminotransferase (AST) and\n        alanine aminotransferase (ALT) < 2.5 times upper limit of normal,bilirubin normal;\n        (10)Creatinine normal OR creatinine clearance \u2265 60 mL/min; (11)Patients have good\n        compliance to treatment and follow-up of acceptance; (12)Forced expiratory volume in one\n        second\uff08FEV1\uff09 \u2265 1.5 litre or \u2265 75% of the reference value; (13)Considered operable (i.e.\n        appropriate organ functions and ability to undergo general anesthesia); (14)No severe or\n        uncontrolled cardiovascular disease; (15)No active uncontrolled infection;\n\n        Exclusion Criteria:\n\n          1. Patient who have distant metastasis\n\n          2. The primary tumor or lymph node already received surgical treatment (except for\n             biopsy);\n\n          3. Patient who received radiotherapy for primary tumor or lymph node;\n\n          4. Patient who received the the epidermal growth factor targeted therapy;\n\n          5. Patient who received chemotherapy or immunotherapy;\n\n          6. Patient who suffered from other malignant tumor;\n\n          7. Epidermal growth factor receptor\uff08EGFR\uff09mutation\uff08-\uff09;\n\n          8. Patient who have taken other drug test within 1 month;\n\n          9. Pregnant woman or Lactating Women and Women in productive age who refuse to take\n             contraception in observation period;\n\n         10. Subject with a severe allergic history or idiosyncratic;\n\n         11. Subject with severe pulmonary and cardiopathic disease history; Refuse or incapable\n             to sign the informed consent form of participating this trial;\n\n         12. Drug abuse or alcohol addicted;\n\n         13. Subject with a Personality or psychiatric diseases, people with no legal; capacity or\n             people with limited capacity for civil conduct;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123381", 
            "org_study_id": "scch2014019"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Patients receive  intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.\nRadiotherapy dose\uff1a95% gross tumor volume\uff08GTV-T\uff09 40Gy/20f\uff0cGTV-N 40Gy/20f\uff0cCTV-T 40Gy/20f\uff0cCTV-N  40Gy/20f.", 
                "intervention_name": "preoperative radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Arm A", 
                "description": "400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4", 
                "intervention_name": "cetuximab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Erbitux", 
                    "C225"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cetuximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "tumor tissue and serum biomarkers", 
            "cetuximab", 
            "preoperative radiotherapy", 
            "esophageal squamous cell carcinoma"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "contact": {
                "email": "litaoxmf@163.com", 
                "last_name": "TAO LI, MD, PhD", 
                "phone": "86-18908178818"
            }, 
            "facility": {
                "address": {
                    "city": "Chengdu", 
                    "country": "China", 
                    "state": "Sichuan", 
                    "zip": "610041"
                }, 
                "name": "Sichuan Cancer Hospital & Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Middle or Lower Thoracic Esophageal Squamous Cell Carcinoma", 
        "overall_contact": {
            "email": "litaoxmf@126.com", 
            "last_name": "TAO LI, MD, PhD", 
            "phone": "86-18908178818"
        }, 
        "overall_official": [
            {
                "affiliation": "Sichuan Cancer Hospital & Institute", 
                "last_name": "YONGTAO HAN, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
                "last_name": "GE WANG, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
                "last_name": "TAIQIAN GONG, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Guangxi medical university affiliated tumor hospital", 
                "last_name": "LONG CHEN, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Guangxi medical university affiliated tumor hospital", 
                "last_name": "NAIQUAN MAO, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Southwest hospital", 
                "last_name": "ZHIHUA RUAN, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Southwest hospital", 
                "last_name": "GANG XIONG, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Xinqiao Hospital\uff0cAffiliated Second Hospitalof Third Military Medical University", 
                "last_name": "JIANGUO SUN, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Xinqiao Hospital\uff0cAffiliated Second Hospitalof Third Military Medical University", 
                "last_name": "GUANGHUI LI, MD.PHD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Xinqiao Hospital\uff0cAffiliated Second Hospitalof Third Military Medical University", 
                "last_name": "DEZHI LI, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Xinqiao Hospital\uff0cAffiliated Second Hospitalof Third Military Medical University", 
                "last_name": "MINGZHANG XIANG, MD,PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Survivin, an inhibitor of apoptosis protein, is highly expressed in most cancers and associated with radiotherapy resistance, increased tumor recurrence, and shorter patient survival.", 
                "measure": "Expression of Survivin protein in Esophageal Squamous Cell Carcinoma before and after Radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "before radiotherapy and 1 months after the radiotherapy"
            }, 
            {
                "description": "p53 (also known as protein 53 or tumor protein 53), is a tumor suppressor protein that in humans is encoded by the TP53 gene.p53 is important in multicellular organisms and involved in preventing cancer.", 
                "measure": "Expression of p53 in Esophageal Squamous Cell Carcinoma before and after Radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "before radiotherapy and 1 months after the radiotherapy"
            }, 
            {
                "description": "Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis.", 
                "measure": "changes of serum vascular endothelial growth factor\uff08VEGF\uff09level before and after radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "before radiotherapy and 1 months after the radiotherapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123381"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sichuan Cancer Hospital and Research Institute", 
            "investigator_full_name": "LI TAO", 
            "investigator_title": "Section Head", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Quality of life (QOL) as measured by European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30\uff09", 
                "measure": "Quality of life (QOL)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "time from randomization to death", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "time from randomization to one of the following events, whichever comes first:\nTumor progression at any time (progression of primary tumor or local lymph nodes, appearance of new lesions)\nRecurrence at local, regional or distant site after surgery\nDeath from any cause", 
                "measure": "PFS\uff08progression-free survival\uff09", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "Time to locoregional failure after R0 resection", 
                "measure": "local control rate\uff08LCR\uff09", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Pathological remission", 
                "safety_issue": "No", 
                "time_frame": "1 months after the end of surgery"
            }, 
            {
                "description": "Grade 3-5 adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0\uff0csuch as esophagitis\u3001pneumonitis and hematologic toxicity", 
                "measure": "grade 3-5 adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }
        ], 
        "source": "Sichuan Cancer Hospital and Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangxi medical university affiliated tumor hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Southwest hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xinqiao Hospital\uff0cAffiliated Second Hospitalof Third Military Medical University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sichuan Cancer Hospital and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}